Therapeutics Areas
Learner Specialties
Expires After
Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care
In this third episode, “Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty and special guest, Caitlin Murphy, DNP to discuss community-based practices for the treatment of NHL and HL. This episode will focus on how to best evaluate patients for and increase participation in clinical trials. Additional conversations will revolve around assessing patient quality of life, recognizing social determinants of health that impact patient care, and recognizing healthcare barriers and inequities in your own patient population. This episode will conclude with a conversation about misperceptions for CAR T-cell therapy and how to best coordinate care for patients receiving either CAR T-cell therapy or bispecific antibody therapy.
Understanding the Impact of Weight on T2D Outcomes
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Setting Up Patients for HCT and Cell Therapy Success
This self-guided course provides practical recommendations and guidance on what hematology/oncology practices can do to improve patient experience and outcomes before their patient reaches a transplant center for consultation for Hematopoietic Cell Transplantation (HCT).
Build Your Own Case Study | Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis and Management
Health Care Providers (HCPs) in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) and its associated risk factors, as well as feel confident around how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.
Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients
Treatment for R/R MCL is complicated, as the disease typically presents in elderly, unfit patients; however, emerging targeted therapy options have shown great promise based on excellent results in clinical trials. In this activity, a taped version of the live symposium at the 17th Annual International Conference on Malignant Lymphoma, expert faculty present therapeutic options, established by evidence-based practice guidelines, for patients with R/R MCL. Symposium learners voted on patient demographics and parameters such as treatment, dosing frequency, and adverse events. The experts crafted their lecture to follow thheir suggestions allowing the case studies to reflect the patients the learners see. The activity concludes with a discussion on engagement between healthcare providers and patients to improve clinical outcomes.
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - The Interconnection of OSA and Disease-related Complications
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape.
Build Your Own Case Study | Obesity: Treating the Whole Patient
Obesity is a chronic, progressive, relapsing disease that impacts health and quality of life. In individuals with obesity, there are many contributors to its development and persistence, including lifestyle, social, and economic factors. If left untreated, obesity can be a primary driver of serious health consequences. By treating obesity first, complications arising from obesity may improve or resolve. Given the severity of the disease, there is a need for clinicians in primary and specialty care settings to diagnose and treat obesity so that patients can receive the most appropriate treatment and care. Evidence-based treatment options, including anti-obesity medications, are emerging for adults and children. In this immersive virtual Build Your Own Case Study | Obesity: Treating the Whole Patient, navigate through your toughest clinical challenges while leading experts reinforce essential topics, such as: Medical consequences and comorbidities of obesity Application of adiposity measures, including BMI and waist circumference Latest clinical evidence of new and emerging anti-obesity medications Best practices in shared decision-making and starting the conversation with your patients
Time Well Spent: Treating Obesity and Diabetes
Community Collective: Time Well Spent – Navigating the Challenges of Treating Obesity and Diabetes is an educational curriculum designed for rural primary care clinicians to enhance outcomes for individuals with obesity through improved diagnosis and use of therapy options to treat type 2 diabetes (T2D).
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy. This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma
In this fourth episode, “Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty as they discuss the benefit of immune checkpoint inhibition for the treatment of HL in patients with relapsed/refractory disease. Discussions will also circulate around how interdisciplinary teams can assist with coordination of patient care, including clinical trials and access to appropriate treatment for those in underrepresented communities.
The Evolution of HCT, Part 4: Addressing Barriers
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 4 in a 5-part series, examining major barriers to HCT and ways to overcome them.
Effective Strategies for Shared Decision-Making in T2D Care
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies
In this second episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty on how to select CAR T-cell and bispecific antibody treatment regimens for NHL according to the latest clinical evidence including safety and efficacy data in accordance with clinical guidelines. Additionally, expert faculty will discuss how to best identify patients who are candidates for CAR T-cell or bispecific antibody therapies as well as how to evaluate the potential of bridging therapy in patients awaiting CAR T-cell therapy. Finally, expert faculty will review treatment-related toxicities with strategies and educational tools that can be used to prevent, monitor, and manage adverse events. This episode will conclude with a discussion between expert faculty and a special guest, Caitlin Murphy, DNP.
Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches
New and emerging advancements in the treatment of follicular lymphoma (FL) are on the horizon. Are you and your clinical teams up for the challenge of testing your skill in applying the latest clinical evidence to these groundbreaking therapies? This independent satellite symposium is an engaging learning experience, where you’ll have the chance to compete against your colleagues in complex clinical cases of follicular lymphoma.
Advances in Non-Hodgkin Lymphoma Care: Navigating New and Emerging Treatments
In this first episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty about unmet needs for patients with NHL based on an understanding of disease- and patient-related characteristics. Additionally, learn how to best assess eligible patients among new and emerging CAR T-cell and bispecific antibody therapies. Expert faculty will also discuss both the mechanisms of action of CAR T-cell and bispecific antibodies. This episode will conclude with a patient case study, which will consist of a dialogue between faculty.
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Screening and Management of OSA
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape. Explore the 3-part on-demand series, Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices for screening, managing, monitoring, and treating patients with OSA
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Dermatology Dialogues | Gaining and Maintaining Flare Control in Moderate-to-Severe Atopic Dermatitis: Enhancing Patient Quality of Life
This 4 part-15 minute segmented vodcast/podcast will unite dermatology and allergy clinicians, who provide care for patients with moderate-to-severe atopic dermatitis (M-S AD).
The Evolution of HCT, Part 3: Donor Availability
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
The Evolution of HCT, Part 1: Basics and Outcomes
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.
The Evolution of HCT, Part 2: Eligibility
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 2 in a 5-part series, covering advances that have expanded eligibility for HCT and considerations for who is a candidate.
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Improving Collaboration Amongst Multidisciplinary Teams to Tackle OSA
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape.
Scroll to Top